What is the recommended medication for treating nightmares?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Medication for Treating Nightmares

Prazosin is recommended as the first-line pharmacological treatment for nightmares, particularly those associated with PTSD, with a starting dose of 1 mg at bedtime gradually increased to an effective dose (typically 3-15 mg). 1, 2

Prazosin Therapy Protocol

  • Prazosin, an alpha-1 adrenergic antagonist, reduces central nervous system adrenergic activity that contributes to nightmare formation 2
  • Start with 1 mg at bedtime and increase by 1-2 mg every few days until effective dose is reached 1, 2
  • Average effective dose is approximately 3 mg, though doses ranging from 1-15 mg have shown efficacy 1
  • Higher doses (9.5-13.3 mg/day) may be needed for military veterans with PTSD-associated nightmares 1, 2
  • Monitor for orthostatic hypotension, especially after the first dose 1, 2
  • Treatment duration in studies ranged from 3-9 weeks with maintained improvement 2, 3

Evidence Supporting Prazosin

  • Multiple Level 1 placebo-controlled studies demonstrated significant reduction in trauma-related nightmares 1
  • Studies included Vietnam combat veterans, military veterans, and civilian trauma victims 1
  • Prazosin significantly reduced "recurrent distressing dreams" as measured by CAPS (Clinician-Administered PTSD Scale) 1, 2
  • Nightmare suppression can occur within one week of prazosin initiation 4
  • Recent evidence has led to a downgrading of the recommendation strength, but prazosin remains the first choice for pharmacologic therapy 1

Alternative Medications

  • Topiramate may be considered as a second-line option, starting at 25 mg/day and titrating up to effect or maximum 400 mg/day 1, 2
  • Trazodone has shown efficacy at a mean dose of 212 mg/day, reducing nightmare frequency from 3.3 to 1.3 nights/week 1, 2
  • Other options with limited evidence include clonidine, atypical antipsychotics, and low-dose cortisol 2
  • Avoid clonazepam, as studies show no improvement in frequency or intensity of nightmares compared to placebo 1
  • Venlafaxine is not recommended as it shows no significant difference from placebo in reducing distressing dreams 1, 2

Clinical Considerations

  • Untreated nightmares significantly impair quality of life, causing sleep avoidance, sleep deprivation, and daytime fatigue 1, 2
  • Successful treatment improves sleep quality, reduces daytime fatigue, and decreases insomnia symptoms 1, 2
  • Patients may maintain concurrent psychotherapy and other psychotropic medications during prazosin treatment 1, 5
  • There may be interactions between prazosin and antidepressant medications that require further investigation 1
  • Prazosin has shown efficacy in both combat-related and non-combat-related trauma nightmares 4, 6

Common Pitfalls and Caveats

  • First-dose hypotension is a concern; consider administering the first dose when the patient can remain recumbent 2, 4
  • Response to prazosin may be reduced in patients taking selective serotonin reuptake inhibitors 1
  • Side effects of prazosin include orthostatic hypotension, dizziness, and headache 7, 4
  • Trazodone side effects include daytime sedation, dizziness, and priapism (which occurred in 5 subjects in one study) 1
  • Benzodiazepines should be avoided as they have not shown efficacy for nightmare treatment 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Pharmacotherapy for PTSD-Associated Nightmares

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Prazosin for treatment of nightmares related to posttraumatic stress disorder.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2008

Research

Prazosin for nightmares in serious illness.

BMJ supportive & palliative care, 2023

Research

Prazosin in the treatment of PTSD.

Journal of psychiatric practice, 2014

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.